Cited 9 times in
Sex as a prognostic factor in adult-type diffuse gliomas: an intergrated clinical and molecular analysis according to the 2021 WHO classification
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석구 | - |
dc.contributor.author | 김민재 | - |
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 김의현 | - |
dc.contributor.author | 김진아 | - |
dc.contributor.author | 문주형 | - |
dc.contributor.author | 이승구 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 한경화 | - |
dc.contributor.author | 박예원 | - |
dc.contributor.author | 안성수 | - |
dc.date.accessioned | 2022-12-22T04:10:55Z | - |
dc.date.available | 2022-12-22T04:10:55Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0167-594X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192067 | - |
dc.description.abstract | Purpose: To investigate whether type-specific sex differences in survival exist independently of clinical and molecular factors in adult-type diffuse gliomas according to the 2021 World Health Organization (WHO) classification. Methods: A retrospective chart and imaging review of 1325 patients (mean age, 54 ± 15 years; 569 females) with adult-type diffuse gliomas (oligodendroglioma, IDH-mutant, and 1p/19q-codeleted, n = 183; astrocytoma, IDH-mutant, n = 211; glioblastoma, IDH-wildtype, n = 800; IDH-wildtype diffuse glioma, NOS, n = 131) was performed. The demographic information, extent of resection, imaging data, and molecular data including O6-methylguanine-methyltransferase promoter methylation (MGMT) promotor methylation were collected. Sex differences in survival were analyzed using Cox analysis. Results: In patients with glioblastoma, IDH-wildtype, female sex remained as an independent predictor of better overall survival (hazard ratio = 0.91, P = 0.031), along with age, histological grade 4, MGMT promoter methylation status, and gross total resection. Female sex showed a higher prevalence of MGMT promoter methylation (40.2% vs 32.0%, P = 0.017) but there was no interaction effect between female sex and MGMT promoter methylation status (P-interaction = 0.194), indicating independent role of female sex. The median OS for females were 19.2 months (12.3-35.0) and 16.2 months (10.5-30.6) for males. No sex difference in survival was seen in other types of adult-type diffuse gliomas. Conclusion: There was a female survival advantage in glioblastoma, IDH-wildtype, independently of clinical data or MGMT promoter methylation status. There was no sex difference in survival in other types of adult-type diffuse gliomas, suggesting type-specific sex effects solely in glioblastoma, IDH-wildtype. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | JOURNAL OF NEURO-ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Brain Neoplasms* / pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glioblastoma* | - |
dc.subject.MESH | Glioma* / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Isocitrate Dehydrogenase / genetics | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methyltransferases | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | World Health Organization | - |
dc.title | Sex as a prognostic factor in adult-type diffuse gliomas: an intergrated clinical and molecular analysis according to the 2021 WHO classification | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Minjae Kim | - |
dc.contributor.googleauthor | Sooyon Kim | - |
dc.contributor.googleauthor | Yae Won Park | - |
dc.contributor.googleauthor | Kyunghwa Han | - |
dc.contributor.googleauthor | Sung Soo Ahn | - |
dc.contributor.googleauthor | Ju Hyung Moon | - |
dc.contributor.googleauthor | Eui Hyun Kim | - |
dc.contributor.googleauthor | Jinna Kim | - |
dc.contributor.googleauthor | Seok-Gu Kang | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Seung-Koo Lee | - |
dc.identifier.doi | 10.1007/s11060-022-04114-4 | - |
dc.contributor.localId | A00036 | - |
dc.contributor.localId | A06334 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A00837 | - |
dc.contributor.localId | A01022 | - |
dc.contributor.localId | A01383 | - |
dc.contributor.localId | A02912 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A04267 | - |
dc.contributor.localId | A05330 | - |
dc.contributor.localId | A02234 | - |
dc.relation.journalcode | J01629 | - |
dc.identifier.eissn | 1573-7373 | - |
dc.identifier.pmid | 35988090 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s11060-022-04114-4 | - |
dc.subject.keyword | Adult-type diffuse gliomas | - |
dc.subject.keyword | Isocitrate dehydrogenase | - |
dc.subject.keyword | O(6)-methylguanine-DNA methyltransferase | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Sex | - |
dc.contributor.alternativeName | Kang, Seok Gu | - |
dc.contributor.affiliatedAuthor | 강석구 | - |
dc.contributor.affiliatedAuthor | 김민재 | - |
dc.contributor.affiliatedAuthor | 김세훈 | - |
dc.contributor.affiliatedAuthor | 김의현 | - |
dc.contributor.affiliatedAuthor | 김진아 | - |
dc.contributor.affiliatedAuthor | 문주형 | - |
dc.contributor.affiliatedAuthor | 이승구 | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.contributor.affiliatedAuthor | 한경화 | - |
dc.contributor.affiliatedAuthor | 박예원 | - |
dc.contributor.affiliatedAuthor | 안성수 | - |
dc.citation.volume | 159 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 695 | - |
dc.citation.endPage | 703 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEURO-ONCOLOGY, Vol.159(3) : 695-703, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.